Logo Cellply

CellPly announces Emiliano Spagnolo as the new CEO

Press release

CellPly announces Emiliano Spagnolo as the new CEO

Former Comecer exec succeeds current Chief Executive Officer and founder Massimo Bocchi to lead the next phase of commercial expansion

BOLOGNA, Italy, July 27, 2023 – CellPly, the pioneer in multiparametric single-cell analysis and automated potency testing for cell therapy, today announced the appointment of Emiliano Spagnolo to the role of CEO, starting from July 14, 2023. Spagnolo joins CellPly after 15 years at Comecer Group, a company commercializing automated solutions for pharmaceutical products manufacturing, including Advanced Therapeutics Medicinal Products (ATMP), where he drove above-market growth for multiple business lines. Spagnolo succeeds current CellPly CEO and founder Massimo Bocchi, who will be moving into a Chief Strategy Officer role with the company.

“Having spent the last 15 years growing the Comecer Group from a family-owned company to a multinational group, I’m excited by the tremendous potential in CellPly capabilities and the VivaCyte Platform to accelerate our understanding of cancer and to enable novel cell and gene therapy development with biopharma partners,” said Emiliano Spagnolo, CEO of CellPly.

 

“The 9 years I spent leading CellPly have been an incredible journey, I am thankful to the investors who believed in our initial idea leaving me the opportunity to guide an extraordinary team in making this idea an actual product”, said Massimo Bocchi, Cellply founder and Chief Strategy Officer. “Emiliano shares our vision about the opportunity to revolutionize the development of cell therapies and immunotherapies by characterizing the immune system function at the single-cell level. He also recognizes the uniqueness of the world-class technical team that throughout the years developed a game-changer technology with passion, motivated by the ambition to support the development of life-saving therapies. Emiliano will bring Cellply to the next level by combining this technical expertise with the commercial and operational growth that the company needs to be a key player in a global market”, added Bocchi.

Before joining CellPly, Spagnolo led the commercial organization at Comecer and the opening of subsidiaries in India, China, Emirates and USA. He also led the transition of Comecer into ATS Automation Group having the opportunity to be part of strategic teams managing M&A operations and company integrations.

“We are excited to get Emiliano on board with us”, said Alessia Zanelli, Chair of the Board at CellPly. “We are all looking forward for extraordinary results during the coming years of Cellply thanks to his experience together with the rest of the entire team at Cellply”, added Zanelli.

continue reading

You may also like

Webinar

Webinar: A new automated potency analysis technique for suspension cells

25 November 2024
Events

Cellply Named in Cohort 2 of EIC Scaling Club for EU Deep Tech Scale-ups

6 November 2024
Events

Cellply Introduces Revolutionary High-Throughput Potency Analysis Technique at SITC 39th Annual Meeting

31 October 2024
Webinar

Webinar: Uncovering hidden immune cell killing to understand anti-tumor activity

2 October 2024
Webinar

Cellply is pleased to announce its participation in European Biotech Week 2024 hosting an open webinar exploring the unique assay flexibility of VivaCyte

9 September 2024
News

Eurofins Biopharma Product Testing (BPT) Italy and Cellply announce strategic partnership to foster cell and gene therapy development through single-cell characterisation

29 August 2024
Webinar

Webinar: Rapid single cell functional characterization for cell therapy potency

12 July 2024
News

Cellply passed the phase 2 of Call4Innovit program and will go to San Francisco

23 May 2024
Events

Advancing TCR-based Cell Therapies & Bispecific Approaches

24 April 2024
Press release

Nature Biotechnology publishes research from DKFZ and Cellply highlighting novel approach for accelerating cellular immunotherapy development

19 March 2024
Events

Dual attendance for Cellply at March’s leading events in the cell therapy industry.

18 March 2024
Events

Launch of VivaCyte® at Advanced Therapies Week 2024

26 January 2024
News

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

17 January 2024
Events

Cellply at Advanced Therapies Week 2024

4 January 2024
News

Cellply – Fesr programme 2021-2027

28 December 2023
Press release

Cellply concludes a new internal round of €3.6 million and extends the round to new investors!

27 September 2023
News

CellPly announces acceptance of one abstract at the CICON23 conference

18 September 2023
News

L’innovazione Cellply in un articolo sulla rivista Le Scienze

4 March 2020
Events

Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting

25 November 2019
News

Cellply wins the €300k Gaetano Marzotto prize and Unicredit StartLab prize

22 November 2018
Events

Cellply invited to present at the World Health Summit 2019

22 October 2018
News

Cellply selected as finalist at Lyfebulb Oncology Award

1 March 2018
Events

Cellply abstract accepted at the AACR 2018 Annual Meeting

4 February 2018
Press release

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

4 November 2016
News

Cellply wins an H2020 SME Instrument Phase 1 grant

20 October 2016
Keep in touch

Need some infos?

Drop us a line or give us a ring. We love to hear from you and are happy to answer any questions.